Written by Jane Aubrey
Nanobiotix has reported complete-cohort results from a Phase 1 study of radiotherapy-activated JNJ-1900, also called NBTXR3, in patients with inoperable, locoregionally recurrent non-small cell lung cancer who were candidates for re-irradiation. The company’s September 14 release describes an MD Anderson-sponsored study in a setting where normal tissue has already received a prior course of radiation and recurrent disease may be difficult to control. That clinical context is central to interpreting the findings: a lower-dose re-irradiation approach that preserves local control could be meaningful, but early, single-arm evidence cannot establish how the strategy compares with available alternatives.
All 24 patients in the pooled dose-escalation and expansion phases completed treatment, according to the release. Investigators reported no dose-limiting toxicities and no Grade 3 or higher adverse events related to JNJ-1900 or to the intratumoral injection procedure. At a median follow-up of 12 months, with an August 2026 data cutoff, the company reported a one-year locoregional control rate of 79%, one-year local progression-free survival of 61% with a median of 13.6 months, and one-year overall survival of 70% with a median of 14.8 months among evaluable subjects.
Those data are encouraging as an early clinical signal, particularly because the study population had recurrent tumors in previously irradiated tissue. But the safety wording requires precision. The absence of Grade 3 or higher events related to the investigational product or the injection is not the same as the absence of serious treatment-course risk. The release also reports Grade 3 radiotherapy-related adverse events in 33% of patients, or eight of 24, and Grade 5 radiotherapy-related adverse events in 8%, or two of 24. Any discussion of tolerability must include both statements, rather than selectively emphasizing the product-attribution result.
JNJ-1900 is a functionalized hafnium-oxide nanoparticle administered through a one-time intratumoral injection and activated by radiotherapy. The proposed mechanism is physical enhancement of tumor-cell death after radiation, followed by an adaptive immune response. The product is designed to allow meaningful local control with lower re-irradiation doses than a patient’s previous radiation course. That hypothesis is clinically compelling because normal-tissue tolerance often constrains a second course of radiation. It remains a hypothesis requiring broader evaluation in carefully designed studies.
The trial design creates clear limitations. This was a Phase 1 study with dose-escalation and expansion components, not a randomized comparison against a control therapy. The cohort was small, and the reported efficacy measures arose in a specialized clinical setting. Local control, local progression-free survival and overall survival can be influenced by patient selection, disease characteristics, concurrent care, imaging schedules and the timing of follow-up. Without a concurrent comparator, it is not possible to determine from these data alone whether outcomes are superior to contemporary re-irradiation approaches or how much any observed effect is attributable to the nanoparticle rather than other elements of care.
The company says the recommended Phase 2 dose was established at 33% of gross tumor volume. Enrollment in the formal dose-escalation and expansion components is complete, and it plans additional enrollment following what it describes as encouraging findings. These next steps matter more than the headline percentages. A development program will need to clarify the intended population, dose consistency, radiation approach, safety monitoring, independent endpoint assessment, follow-up duration and the comparative question it is designed to answer. A randomized study would be especially informative where both local-control benefits and radiation-associated toxicity must be weighed.
The data were presented at the IASLC 2026 World Conference on Lung Cancer. Conference reporting is useful for timely scientific exchange, but readers should distinguish a company release and conference material from a full peer-reviewed publication. The key near-term questions are whether the additional enrollment corroborates the early signal, whether safety remains acceptable when measured across the full treatment course, and whether a subsequent trial can demonstrate a meaningful patient benefit against an appropriate control. For now, the results support continued investigation, not a conclusion about standard clinical practice.
This article is informational and educational only, not medical advice. Decisions about cancer treatment should be made with qualified oncology clinicians using current evidence, safety information and individual circumstances.
